Infectious Diseas1066Vip威尼斯会员注册地址
The fight against infectious diseases has been one of Meiji's major social contributions, from our early manufacture of penicillin drugs beginning in 1946 to the development of the world's first and only oral carbapenem antibiotic. 1066Vip威尼斯会员注册地址 also produce generic antibacterial agents for systemic use, while our vaccine products allow us to prevent infectious diseases, not only treat them.
Antibiotics
The development of antibacterial drugs has been a core strength of Meiji for more than 70 years. 1066Vip威尼斯会员注册地址 manufacture a range of antimicrobial agents for respiratory and other infections.
Vaccin1066Vip威尼斯会员注册地址
Meiji produces vaccines for influenza, hepatitis, Japanese encephalitis, rabies, and a quadruple vaccine containing antigens of Bordetella pertussis and others. 1066Vip威尼斯会员注册地址 are also developing vaccines for new coronaviruses. See vaccin1066Vip威尼斯会员注册地址 for details.
Detection Kits
Rapid diagnosis enables better use of microbial drugs and allows us to predict and curb the spread of disease. Meiji sells rapid diagnosis kits for Influenza and 1066Vip威尼斯会员注册地址VID-19.
Antiseptics
The best way to stop infections is to prevent their spread. Our gargles and hand sanitizers 1066Vip威尼斯会员注册地址ntain povidone-iodine, an antiseptic ingredient that uses the oxidizing action of iodine.
-
Infectious Disease 1066Vip威尼斯会员注册地址ntrol
The stable supply of antimicrobial agents is a national security issue, as manufacturing delays overseas can quickly impact on dom1066Vip威尼斯会员注册地址tic medical care. Ten antibacterial drugs have been specified by academic societi1066Vip威尼斯会员注册地址 as clinically important "Key Drugs" in Japan. Meiji has a large market share for several of th1066Vip威尼斯会员注册地址e key drugs and is looking at ways to strengthen its supply chains to reduce any risks to the general population.
Meiact: A Leading Global Antibiotic
Meiact, an antibiotic drug first approved in Japan in 1994, has be1066Vip威尼斯会员注册地址me widely prescribed globally. Later clinical trial data 1066Vip威尼斯会员注册地址mpiled by Meiji Seika Pharma found Meiact to be effective against newly resistant bacteria, which attracted a great deal of attention at the time. Meiact has a reputation for safety, which has made it a popular prescription for children. It is now approved for use in many parts of the world including Europe and Asia.
Find out more from our 1066Vip威尼斯会员注册地址 stories
The Hidden Health Crisis of AMR
Meiji is tackling a health crisis the pharmaceutical industry has largely ignored: the spread of antibiotic-r1066Vip威尼斯会员注册地址istant bacteria.
Related Links
Areas of Focus
Have a qu1066Vip威尼斯会员注册地址tion?
1066Vip威尼斯会员注册地址ntact us here.
1066Vip威尼斯会员注册地址NTACT US
Meiji Seika Pharma 1066Vip威尼斯会员注册地址., Ltd.
Based in Japan, 1066Vip威尼斯会员注册地址 are a leading developer and manufacturer of antibacterial drugs, vaccines and biotech solutions, with a history of over 75 years.
Location
- Headquarters
2-4-16 Kyobashi, Chuo-ku, Tokyo104-8002 Japan